| HHV-6 isolation and serological assay
HHV-6 isolation and identification were performed as previously described. 18 In brief, peripheral blood mononuclear cells were cocultured with cord blood mononuclear cells. Viral isolation was determined based on obvious morphologic changes of the cultured cells, such as characteristics of pleomorphic, balloon-like large cells.
The presence of HHV-6B was confirmed by immunofluorescence staining of the cocultures with a specific HHV-6B monoclonal antibody (OHV-3; provided by T. Okuno, Department of Microbiology, Hyogo College of Medicine, Hyogo, Japan). Pretransplant HHV-6
Immunoglobulin G antibody titers were measured by indirectimmunofluorescence assay as previously described. 5 
| Monitoring of HHV-6B, CMV, and EBV DNA
Viral DNA was extracted from serially collected peripheral blood mononuclear cells using the QIAamp Blood Kit (QIAGEN, Chatsworth, CA, USA). After extraction, the DNA was eluted in 100 μL of TE buffer and stored at −20°C. Real-time PCR for detection of the 3 human herpesviruses, CMV, 19 EBV, 20 and HHV-6B, was carried out in 10 μL of extracted DNA. The details of the real-time PCR methods for measuring viral DNA loads were previously described. [19] [20] [21] The detection limit of the assays was 10 copies/tube. If 1.0 × 10 4 copies/μg of HHV-6 DNA was detected in peripheral blood mononuclear cells and/ or HHV-6 viremia was demonstrated, we defined it as HHV-6 infection. Additionally, primary infection and reactivation of the virus were distinguished based on pretransplant HHV-6 serostatus. If HHV-6-infected patient was seronegative before transplant, we thought that the patient received primary HHV-6 infection. CMV and EBV infections were defined as 1.0 × 10 3 copies/μg DNA. CMV was monitored by the antigenemia assay using C7HRP method. CMV infection was defined as 1 CMV antigen cell/50 000 cells. CMV antigenemia was examined twice a week during 1 month after transplant in all recipients.
| Patient management
All of the patients included in this study received transplants from their parents. The postoperative immunosuppressant protocol was started with continuous intravenous infusions of CsA (CsA; Sandimmun) or FK (FK; Prograf) with mPSL at a dose of 2 mg/kg on POD 1-3, 1 mg/kg on POD 4-6, and 0.5 mg/kg on POD 7-9. Once the patients could tolerate enteral nutrition, each medication was switched to the oral form and MMF was started at a dose of 10-25 mg/kg. PSL was continuously administered for 3 months following surgery at a dose of 0.25 mg/kg on POD 10-12, 0.125 mg/kg on POD 13-15, and 0.05-0.1 mg/kg thereafter. MMF administration continued for 1 year following surgery.
Trough serum levels were maintained at 200-300 μg/L and 2-6 μg/L for the CsA group and FK group, respectively. We suspected graft rejection from elevated liver transaminase and serum bilirubin. However, no liver biopsy was routinely carried out in those recipients. In suspected cases of organ rejection, mPSL was administered in 10 mg/kg once. γ-globulin was administered (0.1-0.25 g/kg, the maximum was 2. 
| Statistical analysis
All calculations were performed using JMP version 10 statistical soft- 
| Patient population and risk factors for HHV-6B infection
Patient characteristics are shown in Table 1 . Recipients with HHV-6B infection (median, range: 13 months old, 7-160 months old) were significantly younger than those without HHV-6B infection (median, range: 64 months old, 15-129 months old; P < .001). Table 2 ).
| Clinical events associated with HHV-6B infection
Correlations between HHV-6B infection and clinical events are shown in Table 3 . The occurrence of unexplained fever was
TA B L E 1 Patients characteristics and risk for HHV-6B infection

HHV-6B infection
Odds ratio P value Positive (n = 14)
Negative (n = 19) significantly higher in recipients with HHV-6B infection (11/14) than those without infection (6/19) (P = .013). Neither skin rashes nor central nervous system manifestations were observed in any of the recipients during the observation period. No significant differences in the frequencies of CMV and EBV infections were demonstrated between the recipients with and without HHV-6B infection.
| Changes in laboratory data associated with HHV-6B infection
The laboratory findings were compared between the recipients with and without HHV-6B infection ( Figure 1A,B) . ALT levels at weeks 8 and 9 after transplantation were significantly higher in the recipi- Fisher's exact test, significant value is P < .05.
TA B L E 3 Clinical events associated with HHV-6B Interestingly, AST levels between the recipients with and without HHV-6 infection remained similar during the same time period ( Figure 1A) . Furthermore, no statistical differences were demonstrated in the levels of gamma-glutamyl transpeptidase and total bilirubin between the recipients with and without HHV-6 infection (data not shown).
| Mortality associated with HHV-6B infection
We analyzed the relationship between HHV-6B infection and patient survival (Figure 2) . No statistical difference was demonstrated between the 2 groups (P = .313). None of the 14 recipients with HHV-6B infection died, but 2 of the 19 recipients without HHV-6B infection died. Both of the patients had graft loss, despite one patient having received retransplantation, and their cause of death was sepsis.
| Kinetics of HHV-6B DNA after ganciclovir treatment
Five of the 33 recipients were treated with ganciclovir in response to CMV antigenemia. CMV and HHV-6B DNA loads were compared during the treatment period of 2 weeks (Figure 3 ). CMV DNA loads decreased immediately after ganciclovir administration; however, HHV-6B DNA loads were stable in 4 of 5 recipients. Although HHV-6 DNA load increased significantly in one recipient after ganciclovir treatment, no remarkable clinical symptoms were observed. 12 ; however, a low frequency of HHV-6 infection has been demonstrated in liver transplant recipients. 12, 22 The frequency of HHV-6 infection determined using real-time PCR is affected by assay sensitivity, clinical specimen being tested, and the administration of prophylactic antiviral treatment. 23 The relatively high frequency of HHV-6 infection in this study may be due to the fact that prophylactic ganciclovir treatment was not administered to the LDLT recipients.
| D ISCUSS I ON
We identified 3 risk factors for HHV-6 infection after LDLT. In previous studies, age was not associated with HHV-6 reactivation in adult liver transplant recipients 12, 19 and pediatric and young adult recipients 13 who were seropositive against HHV-6B. However, the young infants and children in our study were largely seronegative and susceptible to primary HHV-6B infection via transplanted grafts. 12 Although seronegative recipients were at high risk for HHV-6B infection based on univariate analysis, no statistical difference was demonstrated by multivariate analysis because we failed to detect any seronegative recipients without HHV-6B infection. A larger sample size is needed to definitively determine whether being seronegative is a risk factor for HHV-6B infection. Thus, these results suggest that younger LDLT recipients, who are largely seronegative, have a high risk for acquiring HHV-6B infection.
Although a high MELD/PELD score identifies a risk factor for various types of infections, 24 no reported studies have evaluated whether MELD/PELD score is a risk factor for HHV-6B infection in LDLT recipients. To the best of our knowledge, this is the first study F I G U R E 2 Survival curves of the recipients with and without HHV-6 infection. Two of the 19 recipients without HHV-6 infection died. Both of the patients had graft loss, despite one patient having received retransplantation, and their cause of death was sepsis. The one died 22 mo later and another died 89 mo later F I G U R E 3 Kinetics of HHV-6 and CMV DNA loads (copies/ μg DNA) in recipients treated with ganciclovir (ganciclovir was administered for 2 wk) due to CMV infection to demonstrate that a high MELD/PELD score or biliary atresia was a risk factor for HHV-6B infection in LDLT. It was difficult to evaluate underlying diseases as a risk factor for HHV-6 infection in previous pediatric studies because most of the examined patients had biliary atresia. 13 However, only one-third of the recipients in this present study were biliary atresia patients. Taken together, these data suggest that recipients with a high MELD/PELD score and biliary atresia should be monitored carefully due to their higher risk for acquiring To evaluate the antiviral effect of ganciclovir against HHV-6B in this cohort, the kinetics of both CMV and HHV-6B DNA loads were 
CO N FLI C T O F I NTE R E S T
The authors declare that there is no conflict of interest. 
AUTH O R S' CO NTR I B UTI
